[{"id":"5549ff6d-d0c0-4524-812c-e784acd2dec2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04305444","created_at":"2021-01-18T20:52:47.509Z","updated_at":"2024-07-02T16:35:49.171Z","phase":"Phase 2","brief_title":"Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas","source_id_and_acronym":"NCT04305444","lead_sponsor":"Zhejiang DTRM Biopharma","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • DTRM-555 • DTRMWXHS-12"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/24/2020","start_date":" 04/24/2020","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-05-02"}]